SureTrader SureTrader
Home > Boards > US Listed > Biotechs >

Inovio Pharmaceuticals, Inc. (INO)

INO RSS Feed
Add INO Price Alert      Hide Sticky   Hide Intro
Moderator: ubernano, TomP1
Search This Board:
Last Post: 9/29/2016 7:51:26 AM - Followers: 417 - Board type: Free - Posts Today: 0

Logo: Inovio

www.inovio.com/

http://finance.yahoo.com/q/ks?s=INO

http://finance.aol.com/company/inovio-biomedical-corporation/ino/ase/institutional-ownership

F
ebruary 12, 2014 Inovio CEO Dr. Joseph Kim rings bell to open trading on NYSE- http://www.youtube.com/watch?v=95yO6hFpbUM


Float: 97.65 M

Shares Outstanding: 127.26 M


Inovio Biomedical Corporation engages in the design, development, and delivery of a new generation of vaccines, called DNA vaccines, focused on cancers and infectious diseases. The company?s SynCon technology enables the design of DNA-based vaccines capable of providing cross-protection against evolving, unmatched strains of pathogens, such as influenza. Inovio?s proprietary electroporation DNA delivery technology uses brief, controlled electrical pulses to increase cellular DNA vaccine uptake. The company also has access to formulation and manufacturing expertise, and technology through its controlling ownership in VGX International. Inovio?s clinical programs include trials for HPV/cervical cancer (therapeutic) and HIV vaccines; and an IND has been filed for an avian influenza vaccine. Its partners and collaborators include Roche,Merck, Tripep, University of Southampton, University of Pennsylvania, HIV Vaccines Trial Network, and National Microbiology Laboratory of the Public Health Agency of Canada. The company was formerly known as Genetronics Biomedical Corp. and changed its name to Inovio Biomedical Corporation in March 2005. The company was founded in 1983 and is based in San Diego, California.

Currently Inovio has 12 clinical studies ( HIV, Influenza, Malaria, Hepatitis B, Hepatitis C, Breast and Lung cancer, Prostate Cancer, Head and Neck cancer, Cervical Cancer, Cervical dysplasia caused by HPV) ongoing from preclinical to phase 2.
 
Sep 10, 2013
Roche and Inovio Pharmaceuticals partner on Inovio's prostate cancer and hepatitis B immunotherapy products. Roche will make an upfront payment of USD $10 million to Inovio. Roche will also provide preclinical R&D support and payments for near-term regulatory milestones as well as payments upon reaching certain development and commercial milestones potentially up to USD $412.5 million. Additional development milestone payments could also be made to Inovio if Roche pursues other indications with INO-5150 or INO-1800.  In addition, Inovio is entitled to receive up to double-digit tiered royalties on product sales.

VGX-3100-Phase 2 Clinical Trial initiated for the treatment Cervical dysplasia (cervical intraepithelial neoplasia or CIN) caused by HPV
Top line data release Mid 2014
May 13, 2014:  Inovio Pharmaceuticals Acquires Early Stage DNA Therapies to Treat Alzheimer's and Multiple Sclerosis
http://finance.yahoo.com/news/inovio-pharmaceuticals-acquires-early-stage-080000624.html?.tsrc=applewf

May 23, 2014: Inovio Pharmaceuticals Announces 1 For 4 Reverse Split
http://finance.yahoo.com/news/inovio-pharmaceuticals-announces-1-4-080000629.html
1-for-4 reverse stock split shall become effective at 5 P.M., Thursday, June 5, 2014, and trading of the Company's common stock on a post-reverse split basis shall commence on Friday, June 6, 2014.


Inovio’s goal is to revolutionize vaccines. With best-in-class immune responses from multiple vaccines in different disease areas, our synthetic vaccine technology is making big strides toward this important goal.



 
 



 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
INO
Current Price
Volume:
Bid Ask Day's Range
SureTrader
PostSubject
#13518  Sticky Note 2016 VALUE DRIVERS & MILESTONES (2nd-Half of 2016 Dr_Thorfin 08/01/16 01:50:30 PM
#4698  Sticky Note Please stay on topic. The only topic to IH Admin [Dan] 08/02/13 01:15:33 PM
#13596   BUDGET Congress passes stopgap government funding bill, $1.1B for Silvr Surfr 09/29/16 07:51:26 AM
#13595   Ticking up slowely, nice :) TomP1 09/22/16 02:58:08 AM
#13594   INO bullish 9.58 stocktrademan 09/21/16 03:36:06 PM
#13593   Zacks Research also provides an analyst broker rating ubernano 09/20/16 06:26:40 PM
#13592   VACCINE FOR ZIKA VIRUS BEING TESTED ubernano 09/17/16 12:08:57 PM
#13591   Glad we passed Phase 2 of Clinical trials. StockPotential 09/15/16 06:23:19 PM
#13590   If there ever was a candidate for "SAVE ubernano 09/12/16 10:32:23 AM
#13589   Great news! StockPotential 09/12/16 10:21:05 AM
#13588   Inovio’s Zika Vaccine Selected As 2016 Technology Breakthrough TomP1 09/12/16 08:28:33 AM
#13587   Thanks nano. hammy3777 09/10/16 10:17:34 AM
#13586   INO split history picture ubernano 09/10/16 09:46:15 AM
#13585   I was in this stock a couple of hammy3777 09/09/16 07:12:51 PM
#13584   http://www.politico.com/story/2016/09/zika-funding-senate-breakthrough-227887 north40000 09/08/16 06:50:36 PM
#13583   Time to buy folks, PPS low. IMO Silvr Surfr 09/08/16 02:04:00 PM
#13581   Puerto Rico trial - how long to get ubernano 08/30/16 12:49:31 PM
#13580   AF, If the vaccine wine maker 08/29/16 07:57:14 PM
#13579   * * $INO Video Chart 08-29-16 * * ClayTrader 08/29/16 05:12:50 PM
#13578   Dr. Kim just did an interview a few Autumnforest 08/29/16 03:59:27 PM
#13577   Inovio Launches Zika Vaccine Trial in Midst of ubernano 08/29/16 10:17:37 AM
#13576   Zika! Nice run up today. Go INO Silvr Surfr 08/29/16 09:52:42 AM
#13575   Inovio Expands Ebola Vaccine Trial ubernano 08/25/16 01:32:42 PM
#13574   Minimizing risk poses unique challenges in Zika vaccine Lorie3168 08/24/16 11:44:52 PM
#13573   GM...Just read that they injected their first recipient Cloudbreak 08/24/16 07:08:13 AM
#13572   like how they go to the slums of mikekrane 08/19/16 08:39:52 AM
#13571   Zika vaccine leaders INO & GOVX need volunteers. remind2 08/19/16 12:00:12 AM
#13570   An interesting development,.... surprised there is not some drkazmd65 08/16/16 01:42:56 PM
#13568   Dr. J. Joseph Kim, Inovio’s President & CEO, ubernano 08/11/16 03:33:26 PM
#13567   *****INO DAY = SELL TODAY 8/9/16 TREND1 08/09/16 09:52:04 PM
#13566   IMO gonna test MA200 support at $8.1 before Dr_Thorfin 08/09/16 10:59:36 AM
#13565   Capital Resources TomP1 08/08/16 08:23:37 AM
#13564   Clinical Development TomP1 08/08/16 08:23:23 AM
#13563   thanks TREND1 08/07/16 01:43:43 PM
#13562   We are the first and so far only TomP1 08/07/16 01:42:33 PM
#13561   Do you have any info on ZIKA trials ? TREND1 08/07/16 01:39:09 PM
#13560   Nasdaq website TomP1 08/07/16 01:39:03 PM
#13559   Good enough for me. TREND1 08/07/16 01:38:13 PM
#13558   Got info from TREND1 08/07/16 01:35:32 PM
#13557   institutional ownership = 27,55% TomP1 08/07/16 01:28:41 PM
#13556   ZIKA VACCINE TREND1 08/07/16 01:21:11 PM
#13555   Short % of Float = 6% TREND1 08/07/16 01:13:36 PM
#13554   Float = 67 M TREND1 08/07/16 01:11:23 PM
#13553   Inst % Owned = 7% TREND1 08/07/16 01:10:32 PM
#13552   INO DAY TREND1 08/07/16 01:08:17 PM
#13551   Inovio Goes It Alone on Hepatitis B Immunotherapy ubernano 08/03/16 03:37:43 PM
#13550   Roche returns second Inovio candidate, ends immunotherapy deal ubernano 08/03/16 03:27:46 PM
#13549   And I thought Roche was a robust money ubernano 08/03/16 02:23:55 PM
#13548   You are correct. Today's drop offers good chance docoroc2 08/03/16 12:54:16 PM
#13547   GOVX well along? You gotta be kidding right ? TomP1 08/03/16 12:25:08 PM
#13546   INO rival GOVX well along with Zika vaccine platform remind2 08/03/16 11:53:24 AM
#13545   Yes and maybe. If a Zika panic breaks out TomP1 08/03/16 11:09:19 AM
PostSubject